![Jan Smeitink](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Actieve functies van Jan Smeitink
Bedrijven | Functie | Begin | Einde |
---|---|---|---|
Khondrion BV
![]() Khondrion BV Pharmaceuticals: MajorHealth Technology Khondrion BV is a Dutch clinical-stage biopharmaceutical company that focuses on discovering and developing therapies for mitochondrial diseases. The company is based in Nijmegen, Netherlands, and was founded in 2012 by Jan Smeitink, who has been the CEO since then. The company's lead drug candidate, sonlicromanol, is a first-in-class, oral small molecule that targets key underlying mechanisms of primary mitochondrial disease. The compound has been granted orphan drug designations for the treatment of various mitochondrial diseases. Khondrion collaborates with a clinical and academic network and patient organizations internationally to accelerate the discovery and development of its potential medicines. | Algemeen Directeur | 01-01-2012 | - |
Oprichter | 01-01-2012 | - |
Loopbaan van Jan Smeitink
Statistieken
Internationaal
Nederland | 2 |
Operationeel
Chief Executive Officer | 1 |
Founder | 1 |
Sectoraal
Health Technology | 2 |
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Verwante bedrijven
Bedrijven in privébezit | 1 |
---|---|
Khondrion BV
![]() Khondrion BV Pharmaceuticals: MajorHealth Technology Khondrion BV is a Dutch clinical-stage biopharmaceutical company that focuses on discovering and developing therapies for mitochondrial diseases. The company is based in Nijmegen, Netherlands, and was founded in 2012 by Jan Smeitink, who has been the CEO since then. The company's lead drug candidate, sonlicromanol, is a first-in-class, oral small molecule that targets key underlying mechanisms of primary mitochondrial disease. The compound has been granted orphan drug designations for the treatment of various mitochondrial diseases. Khondrion collaborates with a clinical and academic network and patient organizations internationally to accelerate the discovery and development of its potential medicines. | Health Technology |
- Beurs
- Insiders
- Jan Smeitink
- Ervaring